Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world.
A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.
Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life.
Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.
With a workforce of over 27,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth.
People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers.
In 2022, Forbes has recognized Grifols as one of the “Best Employers for Women,” one of “America’s Best Large Employers” and one of the “75 Best Companies to Work for” in Spain.
plasmapheresis, plasma derived therapies, diagnostics, intravenous therapies, clinical nutrition, automate drug compounding, drug inventory control, healthcare